Bausch Health Companies Inc.

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
071734107
SEDOL
BFFY852
CIK
0000885590
www.bauschhealth.com
LEI:
©
FIGI: BBG000DC8RC7
BHC
Bausch Health Companies Inc.
GICS: - · Sektor: - · Sub-Sektor: Drug Manufacturers - Specialty & Generic
AI
PROFILER
NAME
Bausch Health Companies Inc.
ISIN
CA0717341071
TICKER
BHC
MIC
XTSE
REUTERS
BHC.TO
BLOOMBERG
BHC CN
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von ACCESS Newswire bereitgestellt.
Mi., 19.02.2025       Bausch Health
CA0717341071

Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidanceFourth Quarter Consolidated Revenues of $2.56 billion, up 6% on a Reported basis and up 9% on an Organic (non-GAAP)1 basis over the prior year periodFull-Year Consolidated Revenues of...
Read More
Bausch Health
Technical Analysis Termsheet Terminal
Permalink
Fr., 14.02.2025       Bausch Health
CA0717341071

LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida on February 24. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's web...
Read More
Bausch Health
Technical Analysis Termsheet Terminal
Permalink
Mo., 10.02.2025       Bausch Health
CA0717341071

Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the opening of the 2025 Salix Gastrointestinal Health Scholars Program appl...
Read More
Bausch Health
Technical Analysis Termsheet Terminal
Permalink
Do., 06.02.2025       Bausch Health
CA0717341071

LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch...
Read More
Bausch Health
Technical Analysis Termsheet Terminal
Permalink
Do., 23.01.2025       Bausch Health
CA0717341071

LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m. U.S. EST to discuss the results and provide a business update. ...
Read More
Bausch Health
Technical Analysis Termsheet Terminal
Permalink
Fr., 17.01.2025       Bausch Health
CA0717341071

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiatio...
Read More
Bausch Health
Technical Analysis Termsheet Terminal
Permalink
Do., 12.12.2024       Bausch Health
CA0717341071

LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Inv...
Read More
Bausch Health
Technical Analysis Termsheet Terminal
Permalink
Do., 05.12.2024       Bausch Health
CA0717341071

LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united t...
Read More
Bausch Health
Technical Analysis Termsheet Terminal
Permalink
Mo., 02.12.2024       Bausch Health
CA0717341071

LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical Officer and Head of R&D. This strategic addition to our leadership team underscores our commitment to innovation, excellence, and enriching li...
Read More
Bausch Health
Technical Analysis Termsheet Terminal
Permalink
Mo., 18.11.2024       Bausch Health
CA0717341071

Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the first look at its late-stage RED-C clinical tr...
Read More
Bausch Health
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S